Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 23.18 USD -0.94%
Market Cap: 163.4m USD
Have any thoughts about
Cidara Therapeutics Inc?
Write Note

Cidara Therapeutics Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cidara Therapeutics Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Cidara Therapeutics Inc
NASDAQ:CDTX
Accounts Payable
$3m
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
21%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
215%
CAGR 5-Years
112%
CAGR 10-Years
59%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%
No Stocks Found

Cidara Therapeutics Inc
Glance View

Market Cap
163.3m USD
Industry
Biotechnology

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

CDTX Intrinsic Value
9.28 USD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cidara Therapeutics Inc's Accounts Payable?
Accounts Payable
3m USD

Based on the financial report for Sep 30, 2024, Cidara Therapeutics Inc's Accounts Payable amounts to 3m USD.

What is Cidara Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
21%

Over the last year, the Accounts Payable growth was -19%. The average annual Accounts Payable growth rates for Cidara Therapeutics Inc have been -3% over the past three years , 2% over the past five years , and 21% over the past ten years .

Back to Top